Physician profile
David Vadala
NPI 1740776897
$806.27
in general payments reported to CMS, 2019-2025
13 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.28 · 2024: $280 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784 · Education: $22.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.67 |
| Education | $22.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $204.13 | 2024-2025 | |
| Travere Therapeutics, INC. | $133.34 | 2024-2025 | Filspari |
| Amgen INC. | $131.79 | 2024-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $66.22 | 2024-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $47.04 | 2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $45.49 | 2024-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $41.95 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $37.39 | 2023-2024 | Lokelma |
| Vifor Pharma, INC. | $26.80 | 2024 | Veltassa |
| Ani Pharmaceuticals, INC. | $20.98 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $18.00 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $16.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vadala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.